QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

EXEL

QT87Exelixis, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
51.91
-0.53-1.01%
OverviewShort InterestFilings
EXELQT87Exelixis, Inc.·NASDAQ
OverviewShort InterestFilings
51.91-1.01%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E16.25EPS (ttm)
3.02
Insider Own4.56%
Shs Outstand251.36M
Perf Week-2.97%
Market Cap13.18BForward P/E13.11EPS next Y3.96Insider Trans0.25%Shs Float-Perf Month6.66%
Enterprise Value13.12BPEG0.41EPS next Q0.85Inst Own-Short Float-Perf Quarter25.81%
Income810.64MP/S5.55EPS this Y16.64%Inst Trans-Short Ratio-Perf Half Y24.78%
Sales2.38BP/B7.00EPS next Y12.38%ROA32.13%Short Interest-Perf YTD18.43%
Book/sh7.70P/C14.65EPS next 5Y2.70%ROE40.21%52W High53.93 -3.75%Perf Year25.51%
Cash/sh3.09P/FCF14.38EPS past 3/5Y-ROIC35.01%52W Low33.76 53.76%Perf 3Y-
Dividend Est.-EV/EBITDA12.93Sales past 3/5Y12.93% 18.62%Gross Margin96.44%Volatility1.85% 2.00%Perf 5Y-
Dividend TTM-EV/Sales5.52EPS Y/Y TTM89.77%Oper. Margin39.43%ATR (14)1.53Perf 10Y-
Dividend Ex-Date-Quick Ratio3.19Sales Y/Y TTM9.54%Profit Margin35.08%RSI (14)55.09Recom2.64
Dividend Gr. 3/5Y-Current Ratio3.26EPS Q/Q40.32%SMA200.72%Beta0.77Target Price47.33
Payout0.00%Debt/Eq0.09Sales Q/Q10.09%SMA506.97%Rel Volume2.47Prev Close52.44
Employees1,147LT Debt/Eq0.08EarningsAug 04SMA20019.37%Avg Volume2.65MPrice51.91
IPO DateApr 17, 2000Option/ShortYes / YesEPS/Sales Surpr.13.73% 0.49%Net Debt/EBITDA-0.06Volume6,545,152Change-1.01%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-20-26ReiteratedBarclaysEqual Weight$44 → $45
Feb-12-26ReiteratedH.C. Wainwright$52 → $54
Feb-11-26ReiteratedStifel NicolausHold$43 → $44
Feb-04-26ReiteratedBarclaysEqual Weight$41 → $44
Feb-02-26ReiteratedMorgan StanleyEqual Weight$48 → $49
Jan-14-26ReiteratedTruist Financial$49 → $51
Jan-08-26ReiteratedH.C. Wainwright$49 → $52
Jan-08-26DowngradeMorgan StanleyOverweight → Equal Weight$44 → $48
Jan-05-26ReiteratedUBSNeutral$38 → $41
Nov-05-25ReiteratedH.C. Wainwright$46 → $49
Latest News
Jun-13-26
Jun-13-2608:08PM
Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation QuestionsYahoo
Jun-10-26
Jun-10-2603:30PM
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?Yahoo
12:25PM
Exelixis Hits High on Growing Sales, Institutional InflowsYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
1/2/2026
FY 2024
1/3/2025
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,3762,3202,169
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A848476
Gross Profit2,2912,2362,092
Selling, General and Administrative Excl. Other522519492
Research and Development812825910
Other Operating Expense212086
Operating Income937872605
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-50-21-85
Net Income Before Taxes1,003941682
Income Taxes170159160
Consolidated Net Income834783521
Net Income From Continuing Operations834783521
Net Income834783521
EPS (Recurring)3.122.881.80
EPS (Basic, Before Extraordinaries)3.122.881.80
EPS (Diluted)3.022.781.76
EBITDA1,016922719
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio17.1915.68—
Price To Sales Ratio5.645.11—
Gross Margin96.4296.3896.45
Operating Margin39.4437.5927.89
Net Margin35.1033.7524.02
Shares Outstanding258272290
Market Capitalization13,39311,854—
Operating Lease Expense
———
Insider Trading Volume
$55.69$51.08$46.46$41.84$37.23● Close Price0.00M5.15M10.30M15.45M20.60MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Eckhardt Sue GailDirectorJun 01 '26Sale50.149,812491,97416,079Jun 03 12:00 AM
WYSZOMIERSKI JACK LDirectorJun 01 '26Sale50.553,925198,409284,384Jun 03 12:00 AM
Aftab DanaEVP, Research and DevelopmentMay 26 '26Sale50.3543,4512,187,758594,741May 28 12:00 AM
Haley Patrick J.EVP, CommercialMay 20 '26Sale49.8132,1101,599,399357,638May 22 12:00 AM
Hefti BrendaSVP and General CounselMay 18 '26Sale50.216,625332,641106,762May 19 12:00 AM
Senner Christopher J.EVP and CFOMay 18 '26Sale50.0034,9011,745,050952,317May 19 12:00 AM
POSTE GEORGEDirectorMay 07 '26Sale45.7160,0002,742,600118,832May 08 12:00 AM
Beckerle Mary CDirectorMay 07 '26Option Exercise23.247,712179,22625,236May 08 12:00 AM
Beckerle Mary CDirectorMay 07 '26Sale48.457,712373,64617,524May 08 12:00 AM
Freire Maria CDirectorMay 07 '26Option Exercise19.7741,268815,868121,453May 08 12:00 AM
Freire Maria CDirectorMay 07 '26Sale46.0020,634949,164100,819May 08 12:00 AM
Aftab DanaEVP, Research and DevelopmentFeb 24 '26Sale44.5047,9182,132,351616,106Feb 26 12:00 AM
Aftab DanaEVP, Research and DevelopmentFeb 19 '26Sale44.3529,8731,324,868664,024Feb 23 12:00 AM
WYSZOMIERSKI JACK LDirectorFeb 18 '26Option Exercise19.7741,268815,868379,516Feb 20 12:00 AM
WYSZOMIERSKI JACK LDirectorFeb 18 '26Sale44.0199,5744,382,252279,942Feb 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR